Skip to content
Thursday 13 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,772.67
-0.56%
DAX
26,299.74
-0.12%
CAC 40
8,650.56
-0.28%
STOXX 50
6,545.47
+0.18%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Thursday 30 April 2026 10:03 pm  |  Updated:  Thursday 30 April 2026 10:05 pm

Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 7.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.

Prothena Corporation plc logo with announcement of Q1 2026 financial results release date, May 7, 2026

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430688502/en/

Contact

Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
[email protected]
[email protected]

Abstract

Prothena announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after close of the U.S. financial markets.

Company Logo
Company Logo
Read more

Prothena to Report Second Quarter 2026 Financial Results on August 6

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Advisory
  • Earnings

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • It’s not just Jason Arday, most of sociology is a scam

  • Revolut takes flight with launch of new airport lounges

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

More from Morning Wire

  • Prothena to Report Second Quarter 2026 Financial Results on August 6

    Business Wire
  • Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

    Business Wire
  • Alkermes plc Reports Second Quarter 2026 Financial Results

    Business Wire
  • Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

    Business Wire
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Business Wire
  • Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

    Business Wire
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook